Abhorring the vacuum: Use of Alzheimer's disease medications in frontotemporal dementia

Expert Review of Neurotherapeutics

Volumn 11, Issue 5, 2011, Pages 709-717

  Kerchner, Geoffrey A ^a   Tartaglia, Maria Carmela ^b   Boxer, Adam L ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; frontotemporal dementia; frontotemporal lobar degeneration; FUS; progressive nonfluent aphasia; semantic dementia; Tau; TDP 43

Indexed keywords

ALCOHOL; AMYLOID; BAPINEUZUMAB; CAFFEINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DRUG RECEPTOR; FLUOXETINE; FUSED IN SARCOMA PROTEIN; GALANTAMINE; MEMANTINE; METHYLPHENIDATE; MINERAL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NICOTINE; NON PRESCRIPTION DRUG; OLANZAPINE; PAROXETINE; PIRACETAM; PLACEBO; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TACRINE; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRAZODONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CELL DEATH; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; HERBAL MEDICINE; HUMAN; IC 50; LIVER TOXICITY; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIMARY PROGRESSIVE APHASIA; PROGRESSIVE NONFLUENT APHASIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEMANTIC DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOPAMINE AGENTS; FRONTOTEMPORAL DEMENTIA; HUMANS; MEMANTINE; OFF-LABEL USE; PHARMACOGENETICS;

EID: 79955677159     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.6     Document Type: Review

References (68)

1. Bei Hu, Ross L, Neuhaus J et al. Off-label medication use in frontotemporal dementia. Am. J. Alzheimers Dis. Other Demen. 25(2), 128-133 (2010). Examines how often cholinesterase inhibitors, memantine and other off-label symptomatic therapies are used for the treatment of frontotemporal dementia (FTD).
2. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24(5), 375-398 (2010).
3. Rascovsky KP, Hodges JR, Kipps CM et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): Current limitations and future directions. Alzheimer Dis. Assoc. Disorders 21(4), S14-S18 (2007). (Pubitemid 350307439)
4. Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51(6), 1546-1554 (1998).
5. Mackenzie I, Neumann M, Bigio E et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol. 119(1), 1-4 (2010).
6. Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796), 130-133 (2006). (Pubitemid 44547757)
7. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132(Pt 11), 2922-2931 (2009).
8. Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 21(4), S64-S69 (2007). (Pubitemid 350307447)
9. Talerico KA, Evans LK. Responding to safety issues in frontotemporal dementias. Neurology 56(11 Suppl. 4), S52-S55 (2001). (Pubitemid 32539649)
10. Perry RJ, Miller BL. Behavior and treatment in frontotemporal dementia. Neurology 56(11 Suppl. 4), S46-S51 (2001). (Pubitemid 32539648)
11. Mendez MF. Frontotemporal dementia: Therapeutic interventions. Front. Neurol. Neurosci. 24, 168-178 (2009).
12. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66(1), 17-22 (2006). (Pubitemid 43739585)
13. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 10(Suppl. 1), 80-84 (1999). (Pubitemid 29348621)
14. Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch. Neurol. 48(8), 796-799 (1991).
15. Pasquier F, Fukui T, Sarazin M et al. Laboratory investigations and treatment in frontotemporal dementia. Annals Neurol. 54(Suppl. 5), S32-S35 (2003). (Pubitemid 36760152)
16. Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 17(5), 267-272 (2002). (Pubitemid 35176057)
17. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: Paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur. Neurol. 49(1), 13-19 (2003). (Pubitemid 35477963)
18. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: A double-blind randomized controlled trial. Psychopharmacology 172(4), 400-408 (2004). (Pubitemid 38650975)
19. Lebert F, Pasquier F. Trazodone in the treatment of behaviour in frontotemporal dementia. Hum. Psychopharmacol. Clin. Exp. 14(4), 279-281 (1999). (Pubitemid 29304492)
20. Bowen D, Procter A, Mann D et al. Imbalance of a serotonergic system in frontotemporal dementia: Implication for pharmacotherapy. Psychopharmacology 196(4), 603-610 (2008).
21. Curtis RC, Resch DS. Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J. Clin. Psychopharmacol. 20(3), 384-385 (2000). (Pubitemid 30318372)
22. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients. Am. J. Alzheimers Dis. Other Demen. 18(4), 205-214 (2003). (Pubitemid 37010729)
23. Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int. J. Geriatr. Psychiatry 18(1), 67-72 (2003). (Pubitemid 36131229)
24. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 353(22), 2335-2341 (2005). (Pubitemid 41713745)
25. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: A neuropsychological evaluation. Int. J. Geriatr. Psychiatry 17(4), 391-392 (2002).
26. Rahman S, Robbins TW, Hodges JR et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 31(3), 651-658 (2006). (Pubitemid 43276981)
27. Goforth HW, Konopka L, Primeau M et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: A case study. Clin. EEG Neurosci. 35(2), 108-111 (2004). (Pubitemid 38623645)
28. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin. Biol. Ther. 10(7), 1121-1130 (2010).
29. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8(10), 783-793 (2009).
30. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin. Interv. Aging 3(2), 211-225 (2008). (Pubitemid 352037861)
31. Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: Is there evidence for disease-modifying effects? Curr. Med. Res. Opin. 25(10), 2439-2446 (2009).
32. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr. Med. Chem. 15(24), 2433-2455 (2008).
33. Hansen LA, Deteresa R, Tobias H, Alford M, Terry RD. Neocortical morphometry and cholinergic neurochemistry in Pick's disease. Am. J. Pathol. 131(3), 507-518 (1988).
34. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am. J. Psychiatry 161(3), 532-538 (2004). (Pubitemid 38326109)
35. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 289(2), 210-216 (2003). (Pubitemid 36068709)
36. Lampl Y, Sadeh M, Lorberboym M. Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann. Pharmacother. 38(11), 1967-1968 (2004). (Pubitemid 39425737)
37. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: An open-label study. Drugs Aging 21(14), 931-937 (2004). (Pubitemid 39626373)
38. Knopman DS, Kramer JH, Boeve BF et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131(Pt 11), 2957-2968 (2008).
39. Kertesz A, Morlog D, Light M et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord. 25(2), 178-185 (2008). The only double-blind, placebo-controlled trial of a cholinesterase inhibitor in FTD; the authors observed no clear benefit. (Pubitemid 351196131)
40. Gorno-Tempini ML, Brambati SM, Ginex V et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 71(16), 1227-1234 (2008).
41. Rabinovici GD, Jagust WJ, Furst AJ et al. Ab amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol. 64(4), 388-401 (2008).
42. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: Behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Ger. Psychiatry 15(1), 84-87 (2007). Reported a worsening of disinhibition and compulsive behaviors in patients with FTD in conjunction with donepezil treatment, highlighting a possible adverse reaction to the medication. (Pubitemid 46106094)
43. Boxer AL, Boeve BF. Frontotemporal dementia treatment: Current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis. Assoc. Disord. 21(4), S79-S87 (2007). (Pubitemid 350307449)
44. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59(7), 1077-1079 (2002).
45. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 60(7), 1094-1097 (2003). (Pubitemid 36418766)
46. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr. Dis. Treat. 5, 237-247 (2009).
47. Parsons CG, Stöffler A, Danysz W. Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 53(6), 699-723 (2007). (Pubitemid 47532143)
48. Kerchner G, Kim A, Choi D. Glutamate-mediated excitotoxicity. In:Ionotropic Glutamate Receptors in the CNS. Jonas P, Monyer H (Eds). Springer-Verlag, Berlin, Germany, 443-469 (1999).
49. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov. 5(2), 160-170 (2006).
50. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13(4), 335-345 (1995). (Pubitemid 26007689)
51. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789-791 (2002). (Pubitemid 35231524)
52. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 443(7113), 768-773 (2006). (Pubitemid 44622680)
53. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. J. Clin. Psychiatry 69(3), 341-348 (2008). (Pubitemid 351549385)
54. Franco KN, Messinger-Rapport B. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. J. Am. Med. Dir. Assoc. 7(3), 201-202 (2006). (Pubitemid 43273659)
55. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 20(5), 459-464 (2005). (Pubitemid 40716339)
56. Cummings JL, Schneider E, Tariot PN, Graham SM, for the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67(1), 57-63 (2006). (Pubitemid 44305462)
57. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: A case series. Alzheimer Dis. Assoc. Dis. 21(2), 164-166 (2007). (Pubitemid 46878979)
58. Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J. Geriatr. Psychiatry 23(7), 754-759 (2008). Open-label study of memantine in FTD. Patients tolerated the medication, but there was no clear beneficial effect. Double-blind, placebo-controlled trials are currently ongoing.
59. Boxer AL, Lipton AM, Womack K et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 23(3), 211-217 (2009). Open-label study of memantine in FTD. Patients tolerated the medication, but there was no clear beneficial effect. Double-blind, placebo-controlled trials are currently ongoing.
60. Matsuoka Y, Jouroukhin Y, Gray AJ et al. A neuronal microtubule- interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325(1), 146-153 (2008). Preclinical report that highlights one anti-tau therapeutic strategy that is currently being tested in clinical trials. Anti-tau therapy may be beneficial not only in Alzheimer's disease, but also in the FTD syndromes driven by tau neuropathology. (Pubitemid 351439178)
61. Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: Practical experience from a Phase 2 trial of TAU-aggregation inhibitor therapy. J. Nutr. Health Aging 13(4), 367-369 (2009).
62. Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr. Opin. Neurol. 21(6), 708-716 (2008).
63. Trojanowski JQ, Duff K, Fillit H et al. New directions for frontotemporal dementia drug discovery. Alzheimers Dement. 4(2), 89-93 (2008). (Pubitemid 351373199)
64. Stamelou M, de Silva R, Arias-Carrion O et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 133(Pt 6), 1578-1590 (2010).
65. Cruts M, Gijselinck I, van der Zee J et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442(7105), 920-924 (2006). (Pubitemid 44285947)
66. Baker M, Mackenzie IR, Pickering-Brown SM et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442(7105), 916-919 (2006). (Pubitemid 44285946)
67. Jiao J, Herl LD, Farese RV, Gao FB. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One 5(5), e10551 (2010). Provides a preliminary, preclinical look at a possible therapeutic strategy aimed at reducing FTD-TAR DNA-binding protein neuropathology.
68. Knopman DS, Jack CR Jr, Kramer JH et al. Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year. Neurology 72(21), 1843-1849 (2009).